SIGA Technologies, Inc.
ST-246 (tecovirimat monohydrate) SUSPENSION FORMULATIONS

Last updated:

Abstract:

The present invention is directed to a dry suspension for reconstitution containing Tecovirimat (ST-246) powder and simethicone. The dry suspension is dispersed in water to provide an aqueous pharmaceutical suspension formulation for oral administration for treating orthopoxvirus infections and/or eczema vaccinatum. The suspension formulation exhibits excellent stability and good dissolution and has an improved taste and texture.

Status:
Application
Type:

Utility

Filling date:

15 Feb 2017

Issue date:

15 Jul 2021